News >

Encorafenib, Binimetinib, and Cetuximab Triplet Improves OS, ORR in BRAF+ CRC

Gina Columbus @ginacolumbusonc
Published: Tuesday, May 21, 2019

Scott Kopetz, MD, PhD, FACP

Scott Kopetz, MD, PhD, FACP

The triplet regimen of encorafenib (Bratovi), binimetinib (Mektovi), and cetuximab (Erbitux) led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E-mutant metastatic colorectal cancer (CRC) who previously received up to 2 lines of therapy, meeting both primary endpoints of the phase III BEACON CRC trial.1

Results showed that the triplet therapy was associated with a median overall survival (OS) of 9.0 months compared with 5.4 months for those who received cetuximab/irinotecan-containing treatment (HR, 0.52; 95% CI, 0.39-0.70; P <.0001). The overall response rate (ORR), as assessed by blinded independent central review (BICR), was 26.1% and 1.9%, respectively (P <.0001).

Array BioPharma, Inc., the manufacturer of encorafenib and binimetinib, stated in a press release that it intends to submit these data for marketing approval in the second half of 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication